Is Dynavax Technologies Stock a Buy?

Biopharma Dynavax Technologies (NASDAQ: DVAX) is one of many companies racing to develop a COVID-19 vaccine. Like many coronavirus-focused companies, Dynavax has seen its shares rise on the ongoing concern related to the pandemic -- in its case, by 50% year to date.

While investors may consider these biotech stocks as potential paths to riches, they are also prone to see their share prices fluctuate based on recent headlines. There are plenty of companies in this space racing for a potential coronavirus treatment, and it is equally important for investors to understand the dynamics of each company. Dynavax offers more for investors than the typical coronavirus-focused company, however. It has an approved vaccine with huge commercial opportunity, and the potential to develop a platform that could bolster the treatment of a coronavirus vaccine.

Let's take a closer look.

Continue reading

Source Fool.com